We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+1.29%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$330M
AUM Growth
+$135M
Cap. Flow
+$130M
Cap. Flow %
39.57%
Top 10 Hldgs %
74.15%
Holding
31
New
9
Increased
11
Reduced
2
Closed
8

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$24.8M
2
UNH icon
UnitedHealth
UNH
+$23.2M
3
ASND icon
Ascendis Pharma A/S
ASND
+$18.8M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.8M
5
ARGX icon
argenx
ARGX
+$17.4M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$24.3M
2
MCK icon
McKesson
MCK
+$18.1M
3
GILD icon
Gilead Sciences
GILD
+$10M
4
ILMN icon
Illumina
ILMN
+$9.58M
5
INSM icon
Insmed
INSM
+$7.77M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
Gilead Sciences
GILD
$162B
– –
-89,453
Closed -$10M
ILMN icon
27
Illumina
ILMN
$31B
– –
-120,729
Closed -$9.58M
INSM icon
28
Insmed
INSM
$21.4B
– –
-101,859
Closed -$7.77M
MCK icon
29
McKesson
MCK
$100B
– –
-26,944
Closed -$18.1M
MRUS
30
DELISTED
Merus
MRUS
– –
-156,915
Closed -$6.6M
STVN icon
31
Stevanato
STVN
$5.42B
– –
-175,681
Closed -$3.59M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Tri Locum Partners held 31 positions worth $330M, up 69% from $195M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Tri Locum Partners deployed $130M of net new capital in Q2 2025, opening 9 new positions and adding to 11 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 89,525 shares worth $29.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was GeneDx Holdings, an estimated $1.98M trimmed.

  • Tri Locum Partners's largest Q2 2025 buy was Alnylam Pharmaceuticals: 89,525 shares worth $29.2M.
  • Tri Locum Partners added most to Ascendis Pharma A/S in Q2 2025, an estimated $18.8M increase.
  • Tri Locum Partners's biggest Q2 2025 reduction was GeneDx Holdings, cutting an estimated $1.98M.
  • Tri Locum Partners fully exited Cigna in Q2 2025, selling an estimated $24.3M.
  • Tri Locum Partners's ten largest holdings make up 74% of its $330M portfolio in Q2 2025.
  • Tri Locum Partners opened 9 new positions and closed 8 in Q2 2025.
  • Tri Locum Partners's portfolio value rose 69% quarter-over-quarter to $330M.

Based on Tri Locum Partners's 13F filing for Q2 2025, filed 14 Aug 2025.